Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Pedro Miranda Afonso"'
Autor:
Grace C. Zhou, Ziyun Wang, Anushka K. Palipana, Eleni-Rosalina Andrinopoulou, Pedro Miranda Afonso, Gary L. McPhail, Christopher M. Siracusa, Emrah Gecili, Rhonda D. Szczesniak
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-9 (2024)
Abstract Background Modulator therapies that seek to correct the underlying defect in cystic fibrosis (CF) have revolutionized the clinical landscape. Given the heterogeneous nature of lung disease progression in the post-modulator era, there is a ne
Externí odkaz:
https://doaj.org/article/9daae516b59548be875e50f586862f95
Autor:
Lukas K. van Vugt, Marieke van der Zwan, Marian C. Clahsen-van Groningen, Madelon van Agteren, Daphne M. Hullegie-Peelen, Brenda C. M. De Winter, Marlies E. J. Reinders, Pedro Miranda Afonso, Dennis A. Hesselink
Publikováno v:
Transplant International, Vol 36 (2023)
Alemtuzumab is used as lymphocyte-depleting therapy for severe or glucocorticoid-resistant kidney transplant rejection. However, the long-term efficacy and toxicity of alemtuzumab therapy are unclear. Therefore, all cases of alemtuzumab anti-rejectio
Externí odkaz:
https://doaj.org/article/cfd685a2a41d4895a6c64720351229a2
Autor:
Sara Lomelino Pinheiro, Pedro Miranda Afonso, Inês Lemos Damásio, Joana Simões‐Pereira, Tiago Nunes da Silva, Valeriano Leite
Publikováno v:
Clinical Endocrinology. Wiley-Blackwell Publishing Ltd
Objective: The clinical relevance of solid/trabecular (ST) growth in papillary thyroid carcinoma (PTC) is unclear. In this study, we investigated the impact of any amount of ST growth on tumour characteristics and patient outcomes. Furthermore, we ev